References
- Cooke C B, Krenacs L, Stetler-Stevenson M, Greiner T C, Raffeld D W, Kingma D W, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entitiy of cytotoxic γδ T-cell origin. Blood 1996; 88: 4265–4274
- Wlodarska I, Martin-Garcia N, Achten R, De Wolf-Peeters C, Pauwels P, Tulliez M, et al. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer 2002; 33: 243–251
- Chien Y, Bonneville M. Gamma delta T cell receptors. Cell Mol Life Sci 2006; 63: 2089–2094
- Dayharsh G A, Loftus E V, Sandborn W J, Tremaine W J, Zinsmeister A R, Witzig T E, et al. Epstein-barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathiprine or 6-mercaptopurine. Gastroenterol 2002; 122: 72–77
- Parmar S, Platanias L. Interferons: mechanisms of action and clinical applications. Current Opin Oncol 2003; 15: 431–439
- Dawei X, Erickson S, Szeps M, Gruber A, Sangfelt O, Einhorn S, et al. Interferon α down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 2000; 96: 4313–4318
- Pichardo D A, Querfeld C, Guitart J, Kuzel T M, Rosen S T. Cutaneous T-cell lymphoma: a paradigm for biological therapies. Leuk Lymphoma 2004; 45: 1755–1765
- Toro J, Liewehr D J, Pabby N, Sorbara L, Raffeld M, Steinberg S M, et al. Gamma-delta T-cell phenotype is associated with a significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003; 101: 3407–3412
- Aviles A, Diaz-Maqueo J C, Garcia E L. Maintenance therapy with interferon-α2b in patients with diffuse large-cell lymphoma. Invest new Drugs 1992; 10: 351–355
- Armitage J, Coiffier B. Activity of interferon-alpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma. Ann Oncol 2000; 11: 359–361
- Simon H, Roberts A, Ritchie D, Grigg A. Graft-versus-lymphoma effect in progressive hepatosplenic gamma/delta T-cell lymphoma. Leuk Lymphoma 2007; 48: 1448–1450
- Simon H, Segar R. Hyper-IgE syndrome associated with an IL-4-producing γ/δ+ T-cell clone. J Allergy Clin Immunol 2007; 119: 246–248
- Kandiel A E, Fraser A J, Korelitz B I, Brensinger C M, Lewis J D. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121–1125
- Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. Leuk Lymphoma 2007; 48: 1410–1413
- Mackey A C, Green L, Liang L, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265–267